| |
| |
|
| Insider
Information: |
Klassen Preston |
| Relationship: |
Director |
| City: |
La Jolla |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
1,398,267 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$399,114 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
1,398,267 |
|
|
| Total
Value |
$399,114 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Orexigen Therapeutics, Inc. |
OREX |
EVP, Global Development |
2015-11-30 |
10,160 |
2013-05-28 |
0 |
Premium* |
|
|
Arena Pharmaceuticals Inc |
ARNA |
EVP and CMO |
2019-10-14 |
3,991 |
2019-01-07 |
0 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
Director |
2023-03-23 |
1,384,116 |
2021-05-20 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
21 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MTCR |
Metacrine, Inc. |
Director |
– • – |
2023-03-23 |
4 |
A |
$0.47 |
$395,839 |
D/D |
842,211 |
1,384,116 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
President & CEO |
• • – |
2023-01-26 |
4 |
S |
$0.41 |
$157,266 |
D/D |
(380,605) |
541,905 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
President & CEO |
• • – |
2022-04-19 |
4 |
S |
$0.50 |
$22,472 |
D/D |
(44,748) |
922,510 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
President & CEO |
• • – |
2022-04-14 |
4 |
A |
$0.00 |
$0 |
D/D |
104,500 |
967,258 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
President & CEO |
• • – |
2022-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
842,211 |
862,758 |
0 |
- |
|
| MTCR |
Metacrine, Inc. |
President & CEO |
• • – |
2021-05-20 |
4 |
B |
$3.64 |
$74,692 |
D/D |
20,547 |
20,547 |
2.81 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-10-14 |
4 |
D |
$47.32 |
$109,262 |
D/D |
(2,309) |
3,991 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-10-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,300 |
6,300 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-01-08 |
4 |
AS |
$44.00 |
$132,000 |
D/D |
(3,000) |
0 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-01-08 |
4 |
OE |
$15.10 |
$45,300 |
D/D |
3,000 |
3,000 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-01-07 |
4 |
AS |
$41.68 |
$667,066 |
D/D |
(16,000) |
0 |
0 |
- |
|
| ARNA |
Arena Pharmaceuticals Inc |
EVP and CMO |
• – – |
2019-01-07 |
4 |
OE |
$15.10 |
$241,600 |
D/D |
16,000 |
16,000 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
EVP, Global Development |
• – – |
2015-11-30 |
4 |
A |
$2.03 |
$8,465 |
D/D |
4,170 |
10,160 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
EVP, Global Development |
• – – |
2015-05-30 |
4 |
A |
$4.17 |
$7,756 |
D/D |
1,860 |
5,990 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2014-11-28 |
4 |
A |
$4.92 |
$7,587 |
D/D |
1,542 |
4,130 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2014-05-30 |
4 |
A |
$5.25 |
$6,920 |
D/D |
1,318 |
2,588 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2013-11-29 |
4 |
A |
$5.34 |
$6,782 |
D/D |
1,270 |
1,270 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2013-07-25 |
4 |
AS |
$7.16 |
$510,000 |
D/D |
(71,229) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2013-07-25 |
4 |
OE |
$1.66 |
$118,240 |
D/D |
71,229 |
71,229 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2013-05-28 |
4 |
AS |
$7.21 |
$207,358 |
D/D |
(28,771) |
0 |
0 |
- |
|
| OREX |
Orexigen Therapeutics, In... |
SVP, Head Global Development |
• – – |
2013-05-28 |
4 |
OE |
$1.66 |
$47,760 |
D/D |
28,771 |
28,771 |
0 |
- |
|
21 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
